Lean Metabolic-Associated Fatty Liver Disease

• Cameron Gofton ^[2] ; McCawley Clark-Dickson ^[2] ; Jacob George ^[1]
  1. [1] University of Sydney

     University of Sydney

     Australia

     
  2. [2] Gastroenterology and Hepatology, Bankstown-Lidcombe Hospital, Eldridge Road, Bankstown, NSW 2200, Australia
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 52, Nº. 3, 2023, págs. 431-444
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Since the nomenclature change from nonalcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD), much work has been undertaken to establish the clinical characteristics as well as the hepatic and extrahepatic complications of the different MAFLD subtypes. Currently, there has been significant work performed to evaluate previously acknowledged evidence in the lean NAFLD population to determine its applicability to the new entity. This article examines recently published data on lean MAFLD cohorts to highlight the prevalence, pathophysiological characteristics, associated liver fibrosis, genetics, hepatic and extrahepatic complications, prognosis, treatment, and research into this unique subtype of MAFLD.